clinical trial · NCT03737812
A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis
AbbVie·phase2·completed·n = 123
Multiple Sclerosis (MS)elezanumabplacebo
brief summary
The purpose of this study is to evaluate the safety and efficacy of elezanumab in participants with progressive Multiple Sclerosis (PMS).
started
Feb 27, 2019
primary completion
Jan 15, 2021
completion
Aug 30, 2021
last updated
Dec 21, 2023
official title
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol